Investors Join Inclinix with PMG Research to create Global Clinical Trial Site and Patient Recruitment Organization, Inclinix-PMG Holdings
A consortium of investors led by Frontier Capital has funded the strategic merger of Inclinix with PMG Research, creating an organization designed to accelerate clinical trial enrollment from beginning to end. The company will be led by J. Tobin Geatz, President and CEO, and Jeffrey Reiniche, CFO.
"This novel business combination will allow sponsors and CROs to bundle the two most important services in a trial: world class sites and patient recruiting," noted Geatz. "We will have more than 120 Principal Investigators and 80 study coordinators, who together with Inclinix's 75+ global Clinical Enrollment Managers, provide our customers rapid enrollment locally and worldwide," he continued.
The company will operate in the short term as two divisions.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
